Shopping Cart

Your shopping cart is currently empty

Deucravacitinib

Name: Deucravacitinib
Brand: TargetMol
SKU: T14687
Price: 54 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T14687Cas No. 1609392-27-9

Alias BMS-986165

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.

Deucravacitinib

🥰Excellent

Purity: 99.42%

Catalog No. T14687Alias BMS-986165Cas No. 1609392-27-9

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$54	In Stock	In Stock
5 mg	$147	In Stock	In Stock
10 mg	$275	In Stock	In Stock
25 mg	$432	In Stock	In Stock
50 mg	$638	In Stock	In Stock
100 mg	$908	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$161	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.42%

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
Targets&IC50	Tyk2 JH2:0.2 nM, IL-12:2–19 nM, IL-23:2–19 nM, IFN-α:2–19 nM, JAK1 JH2:1 nM
In vitro	METHODS: The mean daily percent inhibition of TYK2 was simulated by Deucravacitinib (BMS-986165) (6 mg/12 mg once daily) at clinically relevant concentrations. RESULTS Deucravacitinib (BMS-986165) had minimal effects on IL-2-induced STAT5 phosphorylation (JAK 1/3) and TPO-induced STAT3 phosphorylation (JAK 2/2). [3]
In vivo	METHODS: When mirdametinib was used in combination with Deucravacitinib (BMS-986165) (40 μM) in JW23.3 cells, cell growth was observed. RESULTS Both drugs synergistically inhibited cell proliferation and increased cell apoptosis compared to either drug alone. [4]
Synonyms	BMS-986165

Chemical Properties

Molecular Weight	425.46
Formula	C₂₀H₁₉D₃N₈O₃
Cas No.	1609392-27-9
Smiles	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 84.2 mg/mL (197.9 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.76 mM), Sonication is recommeded.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.3504 mL	11.7520 mL	23.5040 mL	117.5199 mL
5 mM	0.4701 mL	2.3504 mL	4.7008 mL	23.5040 mL
10 mM	0.2350 mL	1.1752 mL	2.3504 mL	11.7520 mL
20 mM	0.1175 mL	0.5876 mL	1.1752 mL	5.8760 mL
50 mM	0.0470 mL	0.2350 mL	0.4701 mL	2.3504 mL
100 mM	0.0235 mL	0.1175 mL	0.2350 mL	1.1752 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH₂O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH₂O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.

All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc